the biologics segment is surely a gem, but 2-3 years behind the small molecule segment (CESS). After they agreed on a partnership with a CDMO the machines have to be built / moved there, then their staff has to be trained by Nanoform staff. And then they are capable of producing GMP bages for their first trials on humans. So the first biologics product is far away from market authorization.
The success of the Nanoenzalumatid (commercial validation of the CESS technology) is the most important thing right now. Because this will decide whether Nanoform needs a cash injection or not.
I don’t want that Nanoform get aquired by a big pharma or CDMO, because the potential here is massive.